NASDAQ:SLDB

Solid Biosciences Stock Insider Trading

Healthcare > Biotechnology

Buy SLDB

*Your capital is at risk

$6.85

+0.270 (+4.10%)

At Close: Jun 03, 2026

Solid Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 7.33. In total, the insiders bought 13.49M and sold 403.46K SLDB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	7.33
● Buy	13.49M shares
● Sell	403.46K shares
76% Buy Activity Weak Positive Correlation
Sell Signal Low Confidence Feb 04, 2026 Analysis Breakdown: Weakened by a contradictory positive Insider Power Score. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 31, 2026 Buy	Common Stock M-Exempt	Ganot Ilan Director	Director	15 000 Value: $102.8K
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Brooks Gabriel Chief Medical Officer	Officer	58 847 Value: $388.4K
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Cumbo Alexander President And CEO	CEO / President	169 401 Value: $1.12M
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Herzich Paul Chief Technology Officer	Officer	54 925 Value: $362.5K
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Tan Kevin CFO & Treasurer	C-Suite Officer	56 647 Value: $373.9K
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Hanrahan Jessie Chief Regulatory Officer	Officer	54 925 Value: $362.5K
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Howton David T Chief Operating Officer	C-Suite Officer	79 341 Value: $523.7K
Jan 29, 2026 Buy	Common Stock M-Exempt	Herzich Paul Chief Technology Officer	Officer	54 925 Value: $362.5K
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Herzich Paul Chief Technology Officer	Officer	85 000 Value: $561.0K
Jan 29, 2026 Buy	Performance Stock Units M-Exempt	Howton David T Chief Operating Officer	C-Suite Officer	79 341 Value: $523.7K
Jan 29, 2026 Buy	Common Stock M-Exempt	Howton David T Chief Operating Officer	C-Suite Officer	79 341 Value: $523.7K
Jan 29, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Howton David T Chief Operating Officer	C-Suite Officer	210 200 Value: $1.39M
Jan 29, 2026 Buy	Performance Stock Units M-Exempt	Brooks Gabriel Chief Medical Officer	Officer	58 847 Value: $388.4K
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Hanrahan Jessie Chief Regulatory Officer	Officer	95 000 Value: $627.0K
Jan 29, 2026 Buy	Common Stock M-Exempt	Cumbo Alexander President And CEO	CEO / President	169 401 Value: $1.12M
Jan 29, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Cumbo Alexander President And CEO	CEO / President	509 850 Value: $3.37M
Jan 29, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Tan Kevin CFO & Treasurer	C-Suite Officer	187 000 Value: $1.23M
Jan 29, 2026 Buy	Common Stock M-Exempt	Tan Kevin CFO & Treasurer	C-Suite Officer	56 646 Value: $373.9K
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Cumbo Alexander President And CEO	CEO / President	254 900 Value: $1.68M
Jan 29, 2026 Buy	Restricted Stock Units A-Award	Tan Kevin CFO & Treasurer	C-Suite Officer	93 500 Value: $617.1K
Jan 29, 2026 Buy	Performance Stock Units M-Exempt	Tan Kevin CFO & Treasurer	C-Suite Officer	56 646 Value: $373.9K
Jan 29, 2026 Buy	Performance Stock Units M-Exempt	Cumbo Alexander President And CEO	CEO / President	169 401 Value: $1.12M
Jan 29, 2026 Buy	Employee Stock Option (Right to Buy) A-Award	Hanrahan Jessie Chief Regulatory Officer	Officer	190 000 Value: $1.25M
Jan 29, 2026 Buy	Common Stock M-Exempt	Hanrahan Jessie Chief Regulatory Officer	Officer	54 925 Value: $362.5K
Jan 29, 2026 Buy	Performance Stock Units M-Exempt	Hanrahan Jessie Chief Regulatory Officer	Officer	54 925 Value: $362.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT SOLID BIOSCIENCES INC.

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technol...

Read Full Profile Here